The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study.
 
Shota Fukuoka
No Relationships to Disclose
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Nobelpharma; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Otsuka (Inst); Takeda (Inst)
 
Atsuo Takashima
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Gilead Sciences (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst)
 
Yosuke Kumekawa
No Relationships to Disclose
 
Takeshi Kajiwara
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Oncology (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akitaka Makiyama
No Relationships to Disclose
 
Tadamichi Denda
Research Funding - Sanofi (Inst)
 
Yukimasa Hatachi
No Relationships to Disclose
 
Takeshi Suto
No Relationships to Disclose
 
Naotoshi Sugimoto
No Relationships to Disclose
 
Kenji Katsumata
No Relationships to Disclose
 
Toshiaki Ishikawa
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Tomomi Kashiwada
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Taiho Pharmaceutical
 
Satoshi Yuki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Masahiko Gosho
Honoraria - Kowa; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Takeda
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Lilly Japan (Inst); Merck Serono (Inst); MSD Oncology (Inst); Taiho Pharmaceutical (Inst)